Infliximab (REVELLEX®) is a chimeric IgG1κ monoclonal antibody against tumor necrosis factor-α
(TNF-α). Infliximab is indicated, for the treatment of rheumatoid arthritis (RA), ankylosing
spondylitis (AS), psoriatic arthritis (PsA), Crohn’s disease (CD, ulcerative colitis (UC) and skin
The first aim of this article is to revisit the indications for the use of Infliximab in RA, AS and PsA.
The second aim is to get an update on the newest insights on the safety and efficacy of the drug.
In this article no comparison with regards to long-term efficacy and safety was made to other